Sirtuins transduce STACs signals through steroid hormone receptors.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 03 2020
Historique:
received: 27 08 2019
accepted: 06 03 2020
entrez: 27 3 2020
pubmed: 27 3 2020
medline: 19 12 2020
Statut: epublish

Résumé

SIRT1 protects against several complex metabolic and ageing-related diseases (MARDs), and is therefore considered a polypill target to improve healthy ageing. Although dietary sirtuin-activating compounds (dSTACs) including resveratrol are promising drug candidates, their clinical application has been frustrated by an imprecise understanding of how their signals are transduced into increased healthspan. Recent work indicates that SIRT1 and orthologous sirtuins coactivate the oestrogen receptor/ER and the worm steroid receptor DAF-12. Here they are further shown to ligand-independently transduce dSTACs signals through these receptors. While some dSTACs elicit ER subtype-selectivity in the presence of hormone, most synergize with 17β-oestradiol and dafachronic acid respectively to increase ER and DAF-12 coactivation by the sirtuins. These data suggest that dSTACs functionally mimic gonadal steroid hormones, enabling sirtuins to transduce the cognate signals through a conserved endocrine pathway. Interestingly, resveratrol non-monotonically modulates sirtuin signalling, suggesting that it may induce hormesis, i.e. "less is more". Together, the findings suggest that dSTACs may be informational molecules that use exploitative mimicry to modulate sirtuin signalling through steroid receptors. Hence dSTACs' intrinsic oestrogenicity may underlie their proven ability to impart the health benefits of oestradiol, and also provides a mechanistic insight into how they extend healthspan or protect against MARDs.

Identifiants

pubmed: 32210296
doi: 10.1038/s41598-020-62162-0
pii: 10.1038/s41598-020-62162-0
pmc: PMC7093472
doi:

Substances chimiques

Caenorhabditis elegans Proteins 0
DAF-12 protein, C elegans 0
ESR1 protein, human 0
Estrogen Receptor alpha 0
Estrogen Receptor beta 0
Gonadal Steroid Hormones 0
Isoflavones 0
Receptors, Cytoplasmic and Nuclear 0
Receptors, Estrogen 0
Estradiol 4TI98Z838E
daidzein 6287WC5J2L
SIRT1 protein, human EC 3.5.1.-
Sirtuin 1 EC 3.5.1.-
Sirtuins EC 3.5.1.-
Resveratrol Q369O8926L

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5338

Références

Sauve, A. A., Wolberger, C., Schramm, V. L. & Boeke, J. D. The biochemistry of sirtuins. Annu. Rev. Biochem. 75, 435–465 (2006).
doi: 10.1146/annurev.biochem.74.082803.133500 pubmed: 16756498 pmcid: 16756498
Haigis, M. C. & Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253–295 (2010).
doi: 10.1146/annurev.pathol.4.110807.092250 pubmed: 20078221 pmcid: 20078221
Longo, V. D. & Kennedy, B. K. Sirtuins in aging and age-related disease. Cell 126, 257–268 (2006).
doi: 10.1016/j.cell.2006.07.002 pubmed: 16873059 pmcid: 16873059
Sebastian, C., Satterstrom, K. F., Haigis, M. C. & Mostoslavsky, R. From sirtuin biology to human diseases: An update. J. Biol. Chem. 287, 42444–42452 (2012).
doi: 10.1074/jbc.R112.402768 pubmed: 23086954 pmcid: 23086954
McBurney, M. W., Clark-Knowles, K. V., Caron, A. Z. & Gray, D. A. SIRT1 is a highly networked protein that mediates the adaptation to chronic physiological stress. Genes Cancer 4, 125–134 (2013).
doi: 10.1177/1947601912474893 pubmed: 24020004 pmcid: 24020004
Borra, M. T., Smith, B. C. & Denu, J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187–17195 (2005).
doi: 10.1074/jbc.M501250200 pubmed: 15749705 pmcid: 15749705
Beher, D. et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74, 619–624 (2009).
doi: 10.1111/j.1747-0285.2009.00901.x pubmed: 19843076 pmcid: 19843076
Sinclair, D. A. & Guarente, L. Small-molecule allosteric activators of sirtuins. Annu. Rev. Pharmacol. Toxicol. 54, 363–380 (2014).
doi: 10.1146/annurev-pharmtox-010611-134657 pubmed: 24160699 pmcid: 24160699
Hubbard, B. P. et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339, 1216–1219 (2013).
doi: 10.1126/science.1231097 pubmed: 23471411 pmcid: 23471411
Dai, H. et al. Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. Nat. Commun. 6, 7645 (2015).
doi: 10.1038/ncomms8645 pubmed: 26134520 pmcid: 4506539
Cao, D. et al. Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. Genes Dev. 29, 1316–1325 (2015).
doi: 10.1101/gad.265462.115 pubmed: 26109052 pmcid: 4495401
Price, N. L. et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15, 675–690 (2012).
doi: 10.1016/j.cmet.2012.04.003 pubmed: 22560220 pmcid: 3545644
Park, S. J. et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148, 421–433 (2012).
doi: 10.1016/j.cell.2012.01.017 pubmed: 22304913 pmcid: 3431801
Hubbard, B. P. & Sinclair, D. A. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci. 35, 146–154 (2014).
doi: 10.1016/j.tips.2013.12.004 pubmed: 24439680 pmcid: 3970218
Houtkooper, R. H., Pirinen, E. & Auwerx, J. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13, 225–238 (2012).
doi: 10.1038/nrm3293 pubmed: 22395773 pmcid: 4872805
Lavu, S., Boss, O., Elliott, P. J. & Lambert, P. D. Sirtuins - novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 7, 841–853 (2008).
doi: 10.1038/nrd2665 pubmed: 18827827
Dixon, R. A. Phytoestrogens. Annu. Rev. Plant Biol. 55, 225–261 (2004).
doi: 10.1146/annurev.arplant.55.031903.141729
Morito, K. et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol. Pharm. Bull. 24, 351–356 (2001).
doi: 10.1248/bpb.24.351 pubmed: 11305594 pmcid: 11305594
Kuiper, G. G. et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138, 863–870 (1997).
doi: 10.1210/endo.138.3.4979 pubmed: 9048584 pmcid: 9048584
An, J. P., Tzagarakis-Foster, C., Scharschmidt, T. C., Lomri, N. & Leitman, D. C. Estrogen receptor β–selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276, 17808–17814 (2001).
doi: 10.1074/jbc.M100953200 pubmed: 11279159
Mueller, S. O., Simon, S., Chae, K., Metzler, M. & Korach, K. S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ERα) and ERβ in human cells. Toxicol. Sci. 80, 14–25 (2004).
doi: 10.1093/toxsci/kfh147 pubmed: 15084758
Gehm, B. D., McAndrews, J. M., Chien, P. Y. & Jameson, J. L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 94, 14138–14143 (1997).
doi: 10.1073/pnas.94.25.14138 pubmed: 9391166
Bayele, H. K. A conserved mechanism of sirtuin signalling through steroid hormone receptors. Biosci. Rep. 39, BSR20193535 (2019).
doi: 10.1042/BSR20193535 pubmed: 31746335 pmcid: 6904774
Antebi, A., Yeh, W. H., Tait, D., Hedgecock, E. M. & Riddle, D. L. daf-12 encodes a nuclear receptor that regulates the dauer diapause and developmental age in C. elegans. Genes Dev. 14, 1512–1527 (2000).
pubmed: 316684 pmcid: 316684
Motola, D. L. et al. Identification of ligands for DAF-12 that govern dauer formation and reproduction in C. elegans. Cell 124, 1209–1223 (2006).
doi: 10.1016/j.cell.2006.01.037 pubmed: 16529801
Yamawaki, T. M. et al. The somatic reproductive tissues of C. elegans promote longevity through steroid hormone signaling. PLoS Biol. 8, e1000468 (2010).
doi: 10.1371/journal.pbio.1000468 pubmed: 20824162 pmcid: 2930862
Bemd, V. D., Kuiper, G. J., Pols, G. G., Van Leeuwen, H. A. & Distinct, J. P. effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem. Biophys. Res. Commun. 261, 1–5 (1999).
doi: 10.1006/bbrc.1999.0864
Pace, P., Taylor, J., Suntharalingam, S., Coombes, R. C. & Ali, S. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J. Biol. Chem. 272, 25832–25838 (1997).
doi: 10.1074/jbc.272.41.25832 pubmed: 9325313
Paech, K. et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277, 1508–1510 (1997).
doi: 10.1126/science.277.5331.1508 pubmed: 9278514
Wittmann, B. M., Sherk, A. & McDonnell, D. P. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 67, 9549–9560 (2007).
doi: 10.1158/0008-5472.CAN-07-1590 pubmed: 17909066 pmcid: 17909066
Boonmuen, N. et al. Licorice root components in dietary supplements are selective estrogen receptor modulators with a spectrum of estrogenic and anti-estrogenic activities. Steroids 105, 42–49 (2016).
doi: 10.1016/j.steroids.2015.11.006 pubmed: 26631549 pmcid: 26631549
Kim, M. Y., Woo, E. M., Chong, Y. T., Homenko, D. R. & Kraus, W. L. Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the DNA binding and transactivation activities of the receptor. Mol. Endocrinol. 20, 1479–1493 (2006).
doi: 10.1210/me.2005-0531 pubmed: 16497729 pmcid: 16497729
Li, S. et al. Formononetin promotes angiogenesis through the estrogen receptor alpha-enhanced ROCK pathway. Sci. Rep. 5, 16815 (2015).
doi: 10.1038/srep16815 pubmed: 26568398 pmcid: 26568398
Suriyani, Y. In silico analysis of formononetin compound as a breast anticancer. Revista Latinoamericana de Hipertensión 13, 579–583 (2018).
Howitz, K. T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191–196 (2003).
doi: 10.1038/nature01960
Wood, J. G. et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430, 686–689 (2004).
doi: 10.1038/nature02789 pubmed: 15254550 pmcid: 15254550
Valenzano, D. R. et al. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Current Biol. 16, 296–300 (2006).
doi: 10.1016/j.cub.2005.12.038
Srinivasan, S. et al. Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α. Nat. Chem. Biol. 9, 326–332 (2013).
doi: 10.1038/nchembio.1214 pubmed: 23524984 pmcid: 23524984
Nwachukwu, J. C. et al. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. eLife. 3, e02057 (2014).
doi: 10.7554/eLife.02057 pubmed: 4017646 pmcid: 4017646
Li, L., Andersen, M. E., Heber, S. & Zhang, Q. Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. J. Mol. Endocrinol. 38, 569–585 (2007).
doi: 10.1677/JME-07-0003 pubmed: 17496158 pmcid: 17496158
Calabrese, E. J. & Baldwin, L. A. Hormesis: U-shaped dose responses and their centrality in toxicology. Trends Pharmacol. Sci. 22, 285–291 (2001).
doi: 10.1016/S0165-6147(00)01719-3 pubmed: 11395156 pmcid: 11395156
Xu, H. et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat. Med. 4, 447–451 (1998).
doi: 10.1038/nm0498-447 pubmed: 9546791 pmcid: 9546791
Arevalo, M. A., Azcoitia, I. & Garcia-Segura, L. M. The neuroprotective actions of oestradiol and oestrogen receptors. Nat. Rev. Neurosci. 16, 17–29 (2015).
doi: 10.1038/nrn3856 pubmed: 25423896 pmcid: 25423896
Morselli, E. et al. The effects of oestrogens and their receptors on cardiometabolic health. Nat. Rev. Endocrinol. 13, 352–364 (2017).
doi: 10.1038/nrendo.2017.12 pubmed: 28304393 pmcid: 28304393
Deroo, B. J. & Korach, K. S. Estrogen receptors and human disease. J. Clin. Invest. 116, 561–570 (2006).
doi: 10.1172/JCI27987 pubmed: 16511588 pmcid: 16511588
Mauvais-Jarvis, F., Clegg, D. J. & Hevener, A. L. The role of estrogens in control of energy balance and glucose homeostasis. Endocr. Rev. 34, 309–338 (2013).
doi: 10.1210/er.2012-1055 pubmed: 23460719 pmcid: 23460719
Jia, M., Dahlman-Wright, K. & Gustafsson, J. Å. Estrogen receptor alpha and beta in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 29, 557–568 (2015).
doi: 10.1016/j.beem.2015.04.008 pubmed: 26303083 pmcid: 26303083
Liu, F. et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat. Neurosci. 11, 334–343 (2008).
doi: 10.1038/nn2057 pubmed: 18297067 pmcid: 18297067
Cui, J., Shen, Y. & Li, R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol. Med. 19, 197–209 (2013).
doi: 10.1016/j.molmed.2012.12.007 pubmed: 23348042 pmcid: 23348042
Morito, K. et al. Interaction of phytoestrogens with estrogen receptors alpha and beta (II). Biol. Pharm. Bull. 25, 48–52 (2002).
doi: 10.1248/bpb.25.48 pubmed: 11824555 pmcid: 11824555
Warnsmann, V., Hainbuch, S. & Osiewacz, H. D. Quercetin-induced lifespan extension in Podospora anserina requires methylation of the flavonoid by the O-methyltransferase PaMTH1. Front. Genet. 9, 160 (2018).
doi: 10.3389/fgene.2018.00160 pubmed: 29780405 pmcid: 29780405
Abd El-Mohsen, M. et al. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br. J. Nutr. 96, 62–70 (2006).
doi: 10.1079/BJN20061810 pubmed: 16869992 pmcid: 16869992
Jackson, R. L., Greiwe, J. S. & Schwen, R. J. Emerging evidence of the health benefits of S-equol, an estrogen receptor b agonist. Nutr. Rev. 69, 432–448 (2011).
doi: 10.1111/j.1753-4887.2011.00400.x pubmed: 21790611 pmcid: 21790611
Bode, L. M. et al. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr. 97, 295–309 (2013).
doi: 10.3945/ajcn.112.049379 pubmed: 23283496 pmcid: 23283496
Pallauf, K. et al. Resveratrol, lunularin and dihydroresveratrol do not act as caloric restriction mimetics when administered intraperitoneally in mice. Sci. Rep. 9, 4445 (2019).
doi: 10.1038/s41598-019-41050-2 pubmed: 30872769 pmcid: 30872769
Howitz, K. T. & Sinclair, D. A. Xenohormesis: sensing the chemical cues of other species. Cell 133, 387–391 (2008).
doi: 10.1016/j.cell.2008.04.019 pubmed: 18455976 pmcid: 18455976
Weiskirchen, S. & Weiskirchen, R. Resveratrol: how much wine do you have to drink to stay healthy? Adv. Nutr. 7, 706–18 (2016).
doi: 10.3945/an.115.011627 pubmed: 27422505 pmcid: 27422505
Mattson, M. P. Hormesis and disease resistance: activation of cellular stress response pathways. Hum. Exp. Toxicol. 27, 155–162 (2008).
doi: 10.1177/0960327107083417 pubmed: 18480142 pmcid: 18480142
Bowers, J. L., Tyulmenkov, V. V., Jernigan, S. C. & Klinge, C. M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinol. 141, 3657–3667 (2000).
doi: 10.1210/endo.141.10.7721
Bhat, K. P. et al. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61, 7456–7463 (2001).
pubmed: 11606380 pmcid: 11606380
Pearson, K. J. et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8, 157–168 (2008).
doi: 10.1016/j.cmet.2008.06.011 pubmed: 18599363 pmcid: 18599363
Berman, A. Y., Motechin, R. A., Wiesenfeld, M. Y. & Holz, M. K. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 1, 35 (2017).
doi: 10.1038/s41698-017-0038-6 pubmed: 28989978 pmcid: 28989978
Barger, J. L. et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 3, e2264 (2008).
doi: 10.1371/journal.pone.0002264 pubmed: 18523577 pmcid: 18523577
Brasnyó, P. et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106, 383–938 (2011).
doi: 10.1017/S0007114511000316 pubmed: 21385509 pmcid: 21385509
Cho, S. J., Jung, U. J. & Choi, M. S. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Brit. J. Nutr. 108, 2166–2175 (2012).
doi: 10.1017/S0007114512000347 pubmed: 22414733 pmcid: 22414733
Zarse, K. et al. Differential effects of resveratrol and SRT1720 on lifespan of adult Caenorhabditis elegans. Horm. Metab. Res. 42, 837–839 (2010).
doi: 10.1055/s-0030-1265225 pubmed: 20925017 pmcid: 20925017
Aquilano, K. et al. Peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1alpha) and sirtuin 1 (SIRT1) reside in mitochondria: possible direct function in mitochondrial biogenesis. J. Biol. Chem. 285, 21590–21599 (2010).
doi: 10.1074/jbc.M109.070169 pubmed: 20448046 pmcid: 20448046
Chen, J. Q., Eshete, M., Alworth, W. L. & Yager, J. D. Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors alpha and beta to human mitochondrial DNA estrogen response elements. J. Cell. Biochem. 93, 358–373 (2004b).
doi: 10.1002/jcb.20178 pubmed: 15368362 pmcid: 15368362
Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109–1122 (2006).
doi: 10.1016/j.cell.2006.11.013 pubmed: 17112576 pmcid: 17112576
Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337–342 (2006).
doi: 10.1038/nature05354 pubmed: 17086191 pmcid: 17086191
Lee, J., Kwon, G., Park, J., Kim, J. K. & Lim, Y. H. Brief Communication: SIR-2.1-dependent lifespan extension of Caenorhabditis elegans by oxyresveratrol and resveratrol. Exp. Biol. Med. 241, 1757–1763 (2016).
doi: 10.1177/1535370216650054
Boily, G., He, X. H., Pearce, B., Jardine, K. & McBurney, M. W. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 28, 2882–2893 (2009).
doi: 10.1038/onc.2009.147 pubmed: 19503100 pmcid: 19503100
Klinge, C. M. et al. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J. Biol. Chem. 280, 7460–7468 (2005).
doi: 10.1074/jbc.M411565200 pubmed: 15615701 pmcid: 15615701
Lu, R. & Serrero, G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol. 179, 297–304 (1999).
doi: 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P pubmed: 10228948 pmcid: 10228948
Chen, Y., Tseng, S. H., Lai, H. S. & Chen, W. J. Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 136, 57–66 (2004).
doi: 10.1016/j.surg.2004.01.017 pubmed: 15232540 pmcid: 15232540
Harper, C. E. et al. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28, 1946–1953 (2007).
doi: 10.1093/carcin/bgm144 pubmed: 17675339 pmcid: 17675339
Catalgol, B., Batirel, S., Taga, Y. & Ozer, N. K. Resveratrol: French paradox revisited. Front. Pharmacol. 3, 141 (2012).
doi: 10.3389/fphar.2012.00141 pubmed: 22822401 pmcid: 22822401
Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753–758 (1997).
doi: 10.1038/39645 pubmed: 9338790 pmcid: 9338790
Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927–937 (1998).
doi: 10.1016/S0092-8674(00)81717-1 pubmed: 9875847 pmcid: 9875847
Förster, C. et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. USA 99, 15578–15583 (2002).
doi: 10.1073/pnas.192561299 pubmed: 12438700 pmcid: 12438700
Imamov, O. et al. Estrogen receptor β regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci. USA 101, 9375–9380 (2004).
doi: 10.1073/pnas.0403041101 pubmed: 15187231 pmcid: 15187231
Foley, E. F., Jazaeri, A. A., Shupnik, M. A., Jazaeri, O. & Rice, L. W. Selective loss of estrogen receptor β in malignant human colon. Cancer Res. 60, 245–248 (2000).
pubmed: 10667568 pmcid: 10667568
Wang, L., Andersson, S., Warner, M. & Gustafsson, J. A. Estrogen receptor (ER)beta knockout mice reveal a role for ERbeta in migration of cortical neurons in the developing brain. Proc. Natl Acad. Sci. USA 100, 703–708 (2003).
doi: 10.1073/pnas.242735799 pubmed: 12515851 pmcid: 12515851
McPherson, S. J. et al. Essential role for estrogen receptor β in stromal-epithelial regulation of prostatic hyperplasia. Endocrinol. 148, 566–574 (2007).
doi: 10.1210/en.2006-0906
Paruthiyil, S. et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64, 423–428 (2004).
doi: 10.1158/0008-5472.CAN-03-2446 pubmed: 14729654 pmcid: 14729654
Gong, P. et al. Transcriptomic analysis identifies gene networks regulated by estrogen receptor α (ERα) and ERβ that control distinct effects of different botanical estrogens. Nucl. Recept. Signal. 12, e001 (2014).
doi: 10.1621/nrs.12001 pubmed: 25363786 pmcid: 25363786
Lagari, V. S. & Levis, S. Phytoestrogens for menopausal bone loss and climacteric symptoms. J. Steroid Biochem. Mol. Biol. 139, 294–301 (2014).
doi: 10.1016/j.jsbmb.2012.12.002 pubmed: 23246986 pmcid: 23246986
Dueregger, A. et al. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients 6, 4491–4519 (2014).
doi: 10.3390/nu6104491 pubmed: 25338271 pmcid: 25338271
Kim, D. et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169–3179 (2007).
doi: 10.1038/sj.emboj.7601758 pubmed: 17581637 pmcid: 17581637
Eick, G. N. & Thornton, J. W. Evolution of steroid receptors from an estrogen-sensitive ancestral receptor. Mol. Cell. Endocrinol. 334, 31–38 (2011).
doi: 10.1016/j.mce.2010.09.003 pubmed: 20837101
Markov, G. V. et al. Origin of an ancient hormone/receptor couple revealed by resurrection of an ancestral estrogen. Sci. Adv. 3, e1601778 (2017).
doi: 10.1126/sciadv.1601778 pubmed: 28435861 pmcid: 5375646
Oberdörster, E. et al. Common phytochemicals are ecdysteroid agonists and antagonists: a possible evolutionary link between vertebrate and invertebrate steroid hormones. J. Steroid Biochem. Mol. Biol. 77, 229–238 (2001).
doi: 10.1016/S0960-0760(01)00067-X pubmed: 11457661
Bledsoe, R. K. et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110, 93–105 (2002).
doi: 10.1016/S0092-8674(02)00817-6 pubmed: 12151000
Takeuchi, S. et al. Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using Chinese hamster ovary cells. Biol. Pharm. Bull. 32, 195–202 (2009).
doi: 10.1248/bpb.32.195 pubmed: 19182375
Nilsson, S., Koehler, K. F. & Gustafsson, J. Å. Development of subtype-selective oestrogen receptor-based therapeutics. Nat. Rev. Drug Discov. 10, 778–92 (2011).
doi: 10.1038/nrd3551 pubmed: 21921919
Paterni, I., Granchi, C., Katzenellenbogen, J. A. & Minutolo, F. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. Steroids 90, 13–29 (2014).
doi: 10.1016/j.steroids.2014.06.012 pubmed: 24971815
Melis, G. B. et al. Lack of any estrogenic effect of ipriflavone in postmenopausal women. J. Endocrinol. Invest. 15, 755–761 (1992).
doi: 10.1007/BF03347647 pubmed: 1491124
Gennari, C. et al. Effect of ipriflavone – a synthetic derivative of natural isoflavones – on bone mass loss in the early years after menopause. Menopause 61(Suppl 1), 9–15 (1998).
Snyder, S. A., Gollner, A. & Chiriac, M. I. Regioselective reactions for programmable resveratrol oligomer synthesis. Nature 474, 461–466 (2011).
doi: 10.1038/nature10197 pubmed: 21697944 pmcid: 3179663
Lappano, R. et al. Structure–activity relationships of resveratrol and derivatives in breast cancer cells. Mol. Nutr. Food Res. 53, 845–858 (2009).
doi: 10.1002/mnfr.200800331 pubmed: 19496085
Gao, Y. & He, C. Anti-proliferative and anti-metastasis effects of ten oligostilbenes from the seeds of Paeonia suffruticosa on human cancer cells. Oncol. Lett. 13, 4371–4377 (2017). 
Xue, Y. Q. et al. Resveratrol oligomers for the prevention and treatment of cancers. Oxid. Med. Cell Longev. 2014, 765832 (2014).
doi: 10.1155/2014/765832 pubmed: 24799982 pmcid: 3988857
Fulda, S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov. Today 15, 757–765 (2010).
doi: 10.1016/j.drudis.2010.07.005 pubmed: 20692359
Fischer, N. et al. The resveratrol derivatives trans-3,5-dimethoxy-4-fluoro-4′-hydroxystilbene and trans-2,4′,5-trihydroxystilbene decrease oxidative stress and prolong lifespan in Caenorhabditis elegans. J. Pharm. Pharmacol. 69, 73–81 (2017).
doi: 10.1111/jphp.12657 pubmed: 27882602

Auteurs

Henry K Bayele (HK)

Department of Structural and Molecular Biology, Division of Biosciences, University College London, Darwin Building, Gower Street, London, WC1E 6BT, United Kingdom. h.bayele@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH